Saad B Omer1. 1. Emory University, Atlanta, Georgia, USA. somer@emory.edu
Abstract
OBJECTIVES: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via breastfeeding and mortality. We now present endpoints through 12 months of age. DESIGN:Infants in Ethiopia, India, and Uganda born to HIV-infected women who chose to breastfeed were randomized to receive single-dose or extended-dose nevirapine. MAIN OUTCOMES: HIV transmission, mortality, HIV transmission or death. RESULTS:Primary analysis included 987 and 903 infants in the single-dose and the extended-dose arms, respectively. HIV transmission was 8.9% in the extended-dose group compared to 10.4% in the single-dose group, but the difference was not significant [risk ratio: 0.87, 95% confidence interval (CI): 0.65-1.15]. Cumulative mortality at 12 months was half in the extended-dose group compared to the single-dose group (risk ratio: 0.53, 95% CI: 0.32-0.85). The impact of extended-dose nevirapine was highest in infants of mothers with CD4 cell count more than 350 cells/μl. Risk ratios for death (risk ratio: 0.38, 95% CI: 0.17-0.84) and HIV transmission or death (risk ratio: 0.54, 95% CI: 0.35-0.85) were statistically significant for the CD4 cell counts more than 350 cells/μl category, whereas none of the risk ratios were significant for the CD4 cell counts 200 cells/μl or less and CD4 cell counts 201-350 cells/μl categories. CONCLUSION: For populations with limited access to HAART, our results provide evidence for the use of extended-dose regimens to prevent infant deaths and increase HIV-free survival in infants of HIV-infected breastfeeding women, particularly for infants of women with CD4 cell counts more than 350 cells/μl.
RCT Entities:
OBJECTIVES: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via breastfeeding and mortality. We now present endpoints through 12 months of age. DESIGN:Infants in Ethiopia, India, and Uganda born to HIV-infectedwomen who chose to breastfeed were randomized to receive single-dose or extended-dose nevirapine. MAIN OUTCOMES: HIV transmission, mortality, HIV transmission or death. RESULTS: Primary analysis included 987 and 903 infants in the single-dose and the extended-dose arms, respectively. HIV transmission was 8.9% in the extended-dose group compared to 10.4% in the single-dose group, but the difference was not significant [risk ratio: 0.87, 95% confidence interval (CI): 0.65-1.15]. Cumulative mortality at 12 months was half in the extended-dose group compared to the single-dose group (risk ratio: 0.53, 95% CI: 0.32-0.85). The impact of extended-dose nevirapine was highest in infants of mothers with CD4 cell count more than 350 cells/μl. Risk ratios for death (risk ratio: 0.38, 95% CI: 0.17-0.84) and HIV transmission or death (risk ratio: 0.54, 95% CI: 0.35-0.85) were statistically significant for the CD4 cell counts more than 350 cells/μl category, whereas none of the risk ratios were significant for the CD4 cell counts 200 cells/μl or less and CD4 cell counts 201-350 cells/μl categories. CONCLUSION: For populations with limited access to HAART, our results provide evidence for the use of extended-dose regimens to prevent infantdeaths and increase HIV-free survival in infants of HIV-infected breastfeeding women, particularly for infants of women with CD4 cell counts more than 350 cells/μl.
Authors: Denise J Jamieson; Charles S Chasela; Michael G Hudgens; Caroline C King; Athena P Kourtis; Dumbani Kayira; Mina C Hosseinipour; Deborah D Kamwendo; Sascha R Ellington; Jeffrey B Wiener; Susan A Fiscus; Gerald Tegha; Innocent A Mofolo; Dorothy S Sichali; Linda S Adair; Rodney J Knight; Francis Martinson; Zebrone Kacheche; Alice Soko; Irving Hoffman; Charles van der Horst Journal: Lancet Date: 2012-04-26 Impact factor: 79.321
Authors: Roger L Shapiro; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Kathleen Powis; Sajini Souda; Claire Moffat; Sikhulile Moyo; Kenneth McIntosh; Erik van Widenfelt; Sheryl Zwerski; Loeto Mazhani; Joseph Makhema; Max Essex Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Carolyne Onyango-Makumbi; Saad B Omer; Michael Mubiru; Lawrence H Moulton; Clemensia Nakabiito; Philippa Musoke; Francis Mmiro; Sheryl Zwerski; Hans Wigzell; Lars Falksveden; Britta Wahren; Gretchen Antelman; Mary Glenn Fowler; Laura Guay; J Brooks Jackson Journal: J Acquir Immune Defic Syndr Date: 2011-12-01 Impact factor: 3.731
Authors: Julie A E Nelson; Ali Fokar; Michael G Hudgens; Kara J Compliment; Justin Tyler Hawkins; Gerald Tegha; Deborah D Kamwendo; Dumbani Kayira; Innocent A Mofolo; Athena P Kourtis; Denise J Jamieson; Charles M Van Der Horst; Susan A Fiscus Journal: AIDS Date: 2015-10-23 Impact factor: 4.177